RU2003122348A - Скрининг антагонистов рецепторов лейкоцитов человека - Google Patents
Скрининг антагонистов рецепторов лейкоцитов человека Download PDFInfo
- Publication number
- RU2003122348A RU2003122348A RU2003122348/15A RU2003122348A RU2003122348A RU 2003122348 A RU2003122348 A RU 2003122348A RU 2003122348/15 A RU2003122348/15 A RU 2003122348/15A RU 2003122348 A RU2003122348 A RU 2003122348A RU 2003122348 A RU2003122348 A RU 2003122348A
- Authority
- RU
- Russia
- Prior art keywords
- cells
- ligand
- receptors
- internalization
- induced
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5052—Cells of the immune system involving B-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (20)
1. Способ скрининга соединений на их способность ингибировать каскады лиганд-индуцированной костимуляторной интернализации рецепторов в иммунокомпетентных клетках человека, отличающийся тем, что указанные иммунокомпетентные клетки инкубируют в условиях, способных индуцировать костимуляторную интернализацию рецепторов в присутствии, по меньшей мере, одного тестируемого соединения, и выявляют супрессии лиганд-индуцированной костимуляторной интернализации рецепторов.
2. Способ по п.1, где указанные иммунокомпетентные клетки представляют собой лейкоциты.
3. Способ по п.2, где указанные лейкоциты представляют собой лимфоциты.
4. Способ по п.3, где указанные лимфоциты представляют собой Т-клетки.
5. Способ по п.4, где указанные T-клетки представляют собой клетки Jurkat.
6. Способ по п.2, где указанные лейкоциты представляют собой антиген-презинтирующие клетки.
7. Способ по п.6, где указанные антиген-презинтирующие клетки являются В-клетками.
8. Способ по любому из пп.1-7, где указанные условия заключают в себе культивирование иммунокомпетентных клеток с овариальными клетками китайского хомячка (CHO), трансфицированных ДНК, которая кодирует, по меньшей мере, один лиганд человека.
9. Способ по п.8, где клетки CHO трансфицированы ДНК, кодирующей, по меньшей мере, один лиганд человека или рецептор, выбранный из группы, содержащей ICAM, CD54(LPA3), CD40, CD80, CD86, CD154(CD40L).
10. Способ по одному из пп.1-9, где тестируемое соединение представляет собой соединение с низкой молекулярной массой.
11. Способ по п.10, где тестируемое соединение имеет молекулярную массу примерно до 500.
12. Способ по любому из пп.1-11, где указанное выявление супрессии проводят проточной цитометрией или конфокальным микроскопическим анализом клеток.
13. Способ по одному из пп.1-12, автоматизированный для проведения скрининга с высоким содержанием (HCS) или среднепроизводительного скрининга (MTS).
14. Способ по одному из пп.1-13, где указанные каскады выбраны из группы лиганд-рецепторных пар, включающих в себя CD40/CD154(CD40L), CD2/LFA3, CD28/CD80, CD86 и CD11/ICAM.
15. Набор для использования при скрининге соединений на их способность ингибировать лиганд-индуцированную костимулированную интернализацию рецепторов в иммунокомпетентных клетках человека, содержащий средство для выращивания иммунокомпетентных клеток человека, средство для индуцирования костимуляторной интернализации рецепторов, средство для инкубирования иммунокомпетентных клеток человека, по меньшей мере, с одним тестируемым соединением, средство для мечения рецепторов, и средство для выявления супрессии лиганд-индуцированной костимуляторной интернализации рецепторов.
16. Набор по п.15, где конъюгат с изотопом или флуоресцентным белком применяют для мечения рецепторов.
17. Набор по п.15 или 16, где проточную цитометрию или конфокальную микроскопию применяют для выявления супрессии лиганд-индуцированной костимуляторной интернализации рецепторов.
18. Иммунорегуляторное лекарственное средство, способное блокировать отрицательную модуляцию лиганд-индуцированного рецептора, таким образом, предупреждая лиганд-индуцированную интернализацию рецепторов.
19. Иммунорегуляторное лирующее лекарственное средство по п.18, представляющее собой соединение с низкой молекулярной массой.
20. Иммунорегуляторное унорегул лекарственное средство по п.18 или 19, представляющее собой соединение с молекулярной массой примерно до 500.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0004781A SE0004781D0 (sv) | 2000-12-22 | 2000-12-22 | A screening assay for antagonists of human leukocyte receptors |
SE0004781-1 | 2000-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2003122348A true RU2003122348A (ru) | 2005-01-27 |
Family
ID=20282361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2003122348/15A RU2003122348A (ru) | 2000-12-22 | 2001-12-20 | Скрининг антагонистов рецепторов лейкоцитов человека |
Country Status (9)
Country | Link |
---|---|
US (1) | US20040106160A1 (ru) |
EP (1) | EP1344063A1 (ru) |
JP (1) | JP2004516037A (ru) |
CN (1) | CN1481504A (ru) |
CA (1) | CA2436777A1 (ru) |
NO (1) | NO20032458L (ru) |
RU (1) | RU2003122348A (ru) |
SE (1) | SE0004781D0 (ru) |
WO (1) | WO2002052268A1 (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201104950D0 (en) * | 2011-03-24 | 2011-05-11 | Univ Birmingham | Immune assay |
CN104977237B (zh) * | 2015-07-01 | 2018-02-23 | 北京理工大学 | 一种原位检测单个活细胞内细胞器中co2生成速率的方法 |
CN113981031A (zh) * | 2021-11-01 | 2022-01-28 | 山西中医药大学 | 一种新型t细胞功能检测方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993025712A1 (en) * | 1992-06-15 | 1993-12-23 | The Regents Of The University Of California | Screening assay for the identification of immunosuppressive drugs |
WO1994014065A1 (en) * | 1992-12-14 | 1994-06-23 | Dana-Farber Cancer Institute, Inc. | Methods for identifying and using immunosuppressant compounds |
EP1095277B1 (en) * | 1998-07-13 | 2003-01-22 | Cellomics, Inc. | A system for cell-based screening |
AU770551B2 (en) * | 1998-12-28 | 2004-02-26 | 4-Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
FR2788602B1 (fr) * | 1999-01-20 | 2002-06-07 | Inst Nat Sante Rech Med | Procede de criblage utile pour identifier des ligands potentiels pour un recepteur capable de s'internaliser |
US6642249B2 (en) * | 2001-07-04 | 2003-11-04 | Active Biotech Ab | Immunomodulating compounds |
-
2000
- 2000-12-22 SE SE0004781A patent/SE0004781D0/xx unknown
-
2001
- 2001-12-20 CA CA002436777A patent/CA2436777A1/en not_active Abandoned
- 2001-12-20 EP EP01272418A patent/EP1344063A1/en not_active Withdrawn
- 2001-12-20 JP JP2002553116A patent/JP2004516037A/ja not_active Withdrawn
- 2001-12-20 US US10/432,726 patent/US20040106160A1/en not_active Abandoned
- 2001-12-20 WO PCT/SE2001/002841 patent/WO2002052268A1/en not_active Application Discontinuation
- 2001-12-20 RU RU2003122348/15A patent/RU2003122348A/ru not_active Application Discontinuation
- 2001-12-20 CN CNA01821066XA patent/CN1481504A/zh active Pending
-
2003
- 2003-05-30 NO NO20032458A patent/NO20032458L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20032458L (no) | 2003-06-18 |
NO20032458D0 (no) | 2003-05-30 |
EP1344063A1 (en) | 2003-09-17 |
SE0004781D0 (sv) | 2000-12-22 |
JP2004516037A (ja) | 2004-06-03 |
CN1481504A (zh) | 2004-03-10 |
WO2002052268A1 (en) | 2002-07-04 |
CA2436777A1 (en) | 2002-07-04 |
US20040106160A1 (en) | 2004-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Matile et al. | Plasmodium falciparum malaria parasite cultures and their use in immunology | |
Van Oers et al. | Expression and release of CD27 in human B-cell malignancies | |
Slifka et al. | Activated and memory CD8+ T cells can be distinguished by their cytokine profiles and phenotypic markers | |
Richardson | Effect of an inhibitor of DNA methylation on T cells. II. 5-Azacytidine induces self-reactivity in antigen-specific T4+ cells | |
Cerwenka et al. | Fas-and activation-induced apoptosis are reduced in human T cells preactivated in the presence of TGF-beta 1. | |
Anderson et al. | Hairy cell leukemia: a tumor of pre-plasma cells | |
Haynes et al. | Interleukin 2, but not other common γ chain–binding cytokines, can reverse the defect in generation of CD4 effector T cells from naive T cells of aged mice | |
Shen et al. | Channel catfish cytotoxic cells: a mini-review | |
McKay et al. | Simultaneous deletion of MyD88 and Trif delays major histocompatibility and minor antigen mismatch allograft rejection | |
Ardavin et al. | Cell surface marker analysis of mouse thymic dendritic cells | |
Martinez et al. | CD30 EXPRESSION IDENTIFIES A FUNCTIONAL ALLOREACTIVE HUMAN T-LYMPHOCYTE SUBSET1 | |
González-Cuadrado et al. | Anti-Fas antibodies induce cytolysis and apoptosis in cultured human mesangial cells | |
CA2063578A1 (en) | T-lymphocyte progenitor cell assay | |
Schwartz et al. | Histamine inhibition of the in vitro induction of cytotoxic T-cell responses | |
Van Deusen et al. | CD70 expression by dendritic cells plays a critical role in the immunogenicity of CD40-independent, CD4+ T cell-dependent, licensed CD8+ T cell responses | |
Remington et al. | The RNA of Toxoplasma gondii | |
Kiyotaki et al. | Herpesvirus saimiri strain 11 immortalizes a restricted marmoset T8 lymphocyte subpopulation in vitro. | |
Peck et al. | Secondary in vitro responses of T lymphocytes to non-H-2 alloantigens self-H-2-restricted responses induced in heterologous serum are not dependent on primary-stimulating non-H-2 alloantigens. | |
RU2003122348A (ru) | Скрининг антагонистов рецепторов лейкоцитов человека | |
Park et al. | Origins of the first HLA specificities | |
Chen et al. | RGD-containing peptides trigger apoptosis in glomerular mesangial cells of adult human kidneys | |
Sen-Majumdar et al. | Differentiation of CD3-4-8-thymocytes in short-term thymic stromal cell culture. | |
C O’Neill et al. | Spleen stroma maintains progenitors and supports long-term hematopoiesis | |
Francis et al. | Production of a lymphokine (macrophage activating factor) by salmon (Salmo salar) leucocytes stimulated with outer membrane protein antigens of Aeromonas salmonicida | |
Vremec et al. | The purification of large numbers of antigen presenting dendritic cells from mouse spleen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20060405 |